🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the battle against superbug strains of the infection, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise worldwide, with figures suggesting in excess of 82 million infections each year. Notably increased rates are reported in the African continent and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the context of growing infection rates, escalating drug resistance and the very limited treatment choices at this time.”

Health officials are increasingly worried about the rise in treatment-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in concurrent days. This medication, which is also used to treat UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This approval marks a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Results and Global Access

As per results detailed in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an equal footing with the typical regimen, which involves two antibiotics. The research included over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the ability to register and commercialise the drug in numerous regions with limited resources.

Clinicians treating patients have expressed hope. The availability of a single-dose, oral treatment of this kind is hailed as a "critical tool" for managing the epidemic. This is deemed vital to reduce the burden of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.